



MedsMatter!

Conversation Series: Front Line Perspectives About the Blue Bag Initiative May 20, 2021

Logistics





Use the **Chat** icon to type your questions or comments.

Raise your hand icon if you want to verbally ask a question.


Information from today's session will be posted in **Chat**.

You may adjust your audio by clicking the caret next to the **Mute** icon.



* Health Quality Innovation Network















The Blue Bag Initiative: Front Line Perspectives





Session Goals



- 1. Identify best Blue Bag Intervention (BBI) practices through today's guest pharmacists' sharing.
- 2. Discover how the data collected in the program can be utilized to improve processes and patient outcomes.
- 3. Determine how you can use the BBI in your setting.
- 4. Share with each other....







Today's Presenters

> Dr. Erin Hickey, PharmD, BCOP

Assistant Professor, Hematology and Oncology Virginia Commonwealth University School of Pharmacy

> Dr. Crystal Perkins, PharmD

Community Pharmacist





Blue on the Horizon: Implementing the Blue Bag Initiative in an Oncology Clinic

Erin Hickey, PharmD, BCOP

- Assistant Professor, VCU School of Pharmacy
- Clinical Pharmacy Specialist, Hematology and Oncology, VCU Health


VCU Gynecologic Oncology Clinic


- Interdisciplinary team
 - 3 Gynecologic Oncologists, OB-GYN fellows & residents
 - Nurse-Practitioner, Nurse Navigator, clinic RNs, clinical trial RN
 - LCSW, genetic counselor, radiologist, pathologist
 - 1 faculty PharmD (started ~1 year ago)
- Patients with ovarian, cervical, endometrial cancers
 - Most 65+ years older or with chronic comorbid conditions
- Surgery, chemotherapy, radiation, supportive care





Cancer as a Chronic Disease







Oral Chemotherapy

 Pharmacist-supported, collaborative oral chemotherapy management programs have been shown to improve:

- Patient understanding/education¹
- Patient adherence¹
- Clinical outcomes (e.g. higher rate of CMR with BCR-ABL TKIs)¹
- Prevention of medication-related problems (e.g, severe side effects, unscheduled admissions, & death)^{2,3}
- Adherence with monitoring standards⁴

Explosion of oral chemotherapy approvals!

Pharmacist-Driven Oral Chemotherap y Program

Busy

surgeon

collabora

tors

Frequent transitions of care and medication-related problems Comorbid patient populati on



Oral Chemo & Blue Bag Initiative

PharmD consulted for new-start oral chemo



- Comprehensive medication review (e.g. medication reconciliation, DDI check)
- Therapy evaluation
- Supportive care medication assessment (e.g., antimicrobial pp)
- Pharm D Orders / prescriptions (attending co-sign)

New start patient education



 Initial counseling visit for oral chemotherapy education (inperson or

teleconference)



Access Coordination



Monitoring

- Partner with authorization technicians. specialty pharmacy, and social work to resolve access issues
- Collaborates to adjudicate PAs (e.g. writing appeal letters)

- PharmD orders labs per standardized intervals (attending cosign)
- PharmD completes CMR. CCM, and lab assessment & monitoring
- Communicates results to MD & patient



Where Blue Bag Fits

BBI DATA

of Blue bags given to participants

of Participants screened / RX reviews completed

of Participants screened with events identified

of Potential adverse drug events identified

of Expired/discontinued medications participants should not be taking

of Narcotic prescriptions participants should not be taking

of Participants who could state how and when they should take their medications

BBI DATA

% of Participants screened who could state how and when they should take their medications

% Participants Screened with pADEs Identified

pADEs Identified per 100 Participants

Expired/ Discontinued Drugs per 100 Participants Screened

Potential Savings Achieved*

CARE COORDINATION	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21	Sep-21	Oct-21	Nov-21	Dec-21	YTD
% of Participants with 80%+ appointment adherence			0.0%	0.0%									0.0%
% of Participants with 80%+ medication adherence			0.0%	100.0%									50.0%
% of Participants with pharmacist provided patient education			0.0%	100.0%									50.0%
% of Participants provided with smoking cessation therapy			0.0%	0.0%									0.0%

VITALS AND LABS	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21	Sep-21	Oct-21	Nov-21	Dec-21	YTD
% of Participants with BP > 140/90			0.0%	0.0%									0.0%
% of Participants with total cholesterol > 200			0.0%	0.0%									0.0%
% of Participants with triglycerides > 150			0.0%	0.0%									0.0%
% of Participants with A1C > 9.0%			0.0%	0.0%									0.0%
% of Participants with blood glucose > 110			0.0%	0.0%									0.0%

→ % with BP >140/90

---- % with triglycerides > 150

LOWER IS BETTER

100.00



	1 24	F.1. 34		24		24	1.1.24		C 24	0 4 04		D 24	1000
PATIENTS IDENTIFIED AT RISK	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21	Sep-21	Oct-21	Nov-21	Dec-21	YTD
% of Participants with possible drug- drug interactions			50.0%	62.5%									60.0%
% of Participants whose pill bottles did not match medication list			0.0%	50.0%									40.0%
% of Participants who stopped taking a medication w/o telling a clinician			0.0%	0.0%									0.0%
% of Participants who started taking a new medication w/o telling a clinician			0.0%	25.0%									20.0%

CARE COORDINATION	Jan-21	Feb-21	Mar-21	Apr-21	May-21	Jun-21	Jul-21	Aug-21	Sep-21	Oct-21	Nov-21	Dec-21	YTD
% of Participants with 80%+			50.000	75.00/									70.00/
appointment adherence			50.0%	75.0%									70.0%
% of Participants with 80%+ medication			F0.00/	07.50/									00.00/
adherence		<u> </u>	50.0%	87.5%			<u> </u>						80.0%
% of Participants with pharmacist			50.0%	87.5%									80.0%
provided patient education			50.0%	07.570									80.0%
% of Participants provided with smoking			0.00/	50.00/									40.0%
cessation therapy	<u>/</u> '	<u> </u>	0.0%	50.0%	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u>/</u> /	<u> </u>	'	<u> </u>	40.0%

Early Successes & Future Goals

Early Successes	Future Goals
 Clinic support of initiative Patient adherence to visits Easy way to objectively collect, report, & summarize pilot impact Student involvement! 	 Demonstrating impact of pilot program at the pharmacy department and Massey Cancer Center levels Designated a Quality Improvement Project of Hematology Oncology & Palliative Care Quality Council Expansion to all oncology clinics Measuring: Oral chemotherapy-specific lab values (e.g. complete blood count, adverse effects) Unanticipated ED visits and hospitalizations Patient satisfaction Demonstrating the impact of pharmacist services on success of patients with cancer on oral chemotherapy Reimbursement for services!



Sharing Questions

What advice or experiences do you have...

- Utilizing Blue Bag Initiative to justify expanded services?
- Applying Blue Bag Initiative to the needs of your specific patient population?

How could you apply the Blue Bag Initiative to the needs of your specific population?



Thank you!

- Cindy Warriner, BS, RPh, CDE
- Health Quality Innovators
- VCU Gynecologic Oncology Clinic collaborators & patients!





Crystal Perkins, PharmD

Pharmacist

Claypool Hill Pharmacy Haysi Drug Center



Front Line Perspectives About the Blue Bag Initiative



Time for Q&A, Comments and Discussion







MedsMatter! Conversation Series

Save the Date:

12:30 p.m. EST

> June 24, 2021: Mind Your Meds

Thank you for participating in today's session!





Blue Bag Contacts for your State....

- Kansas Rosanne Rutkowski rrutkowski@khconline.org
- Missouri Dana Lammert dlammert@hqi.solutions
- South Carolina Cheryl Anderson canderson@thecarolinascenter.org
- Virginia Cindy Warriner
 cwarriner@hqi.solutions

....or contact <u>bluebag@hqi.solutions</u>



CONNECT WITH US

Call 877.731.4746 or visit www.hqin.org



@HQINetworkHealth Quality Innovation Network



